Skip to content

The Outcomes of Living Donor Robotic Assisted Kidney Transplantation

A Retrospective Cohort Study of Prospectively Collect the Outcomes of Recipients After Robot-assisted Kidney Transplantation

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06577805
Acronym
RAKT
Enrollment
400
Registered
2024-08-29
Start date
2020-07-01
Completion date
2025-12-31
Last updated
2024-09-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Transplant; Complications, Renal Failure Chronic

Keywords

robotic surgery

Brief summary

The technology for robot-assisted kidney transplantation (RAKT) has become increasingly advanced, with numerous studies demonstrating comparable outcomes between RAKT surgery and open surgery. This advancement is particularly noteworthy as it extends its suitability to transplant patients with obesity. It will be important to explore the results of robot-assisted kidney transplantation as compared with open surgery or within cohorts.

Interventions

None listed

Sponsors

West China Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

1. living-donor kidney transplant recipients 2. receiving standard triad immunosuppressive regimen

Exclusion criteria

1. active infection 2. multi-organ transplantation 3. malignancy history in the donor and recipient 4. human immunodeficiency virus infection

Design outcomes

Primary

MeasureTime frameDescription
The graft function of recipientsin the follow-up period,about six months to one yearthe graft function of recipients per month after transplant surgery, assessed by the serum creatinine (umol/L) and estimated glomerular function rate (eGFR).

Secondary

MeasureTime frameDescription
total operative timeabout 150 minutes to 300 minutesThe time from the beginning of the procedure to the end of the procedure (minute)

Countries

China

Contacts

Primary ContactTao Lin, M.D.
kidney5@163.com028 85582944

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026